Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2019 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
QNCX on Nasdaq
Shares outstanding
56,260,480
Price per share
$0.27
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
20,143,303
Total reported value
$67,479,982
% of total 13F portfolios
0%
Share change
+8,350,640
Value change
+$28,429,772
Number of holders
67
Price from insider filings
$0.27
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nantahala Capital Management, LLC 10% 0% $9,156,792 +$1,392,249 5,620,422 +18% Nantahala Capital Management, LLC 30 Sep 2025
Sofinnova Partners SAS 2.7% -54% $1,185,734 -$1,188,000 1,197,711 -50% Sofinnova Capital VIII 31 Mar 2025

As of 31 Dec 2025, 67 institutional investors reported holding 20,143,303 shares of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX). This represents 36% of the company’s total 56,260,480 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) together control 33% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Nantahala Capital Management, LLC 4.8% 2,672,429 -13% 0.53% $8,952,637
ADAGE CAPITAL PARTNERS GP, L.L.C. 4% 2,250,000 0.01% $7,537,500
VANGUARD GROUP INC 3.7% 2,084,015 +18% 0% $6,981,450
Woodline Partners LP 3.5% 1,941,542 0.03% $6,504,166
MILLENNIUM MANAGEMENT LLC 2.1% 1,190,352 -14% 0% $3,987,679
IEQ CAPITAL, LLC 1.7% 979,275 -0.2% 0.01% $3,280,571
Almitas Capital LLC 1.7% 930,134 +88% 0.69% $3,115,949
SUPERSTRING CAPITAL MANAGEMENT LP 1.5% 858,711 1.5% $2,876,682
STEMPOINT CAPITAL LP 1.3% 739,264 0.43% $2,476,534
RENAISSANCE TECHNOLOGIES LLC 0.96% 538,100 +15% 0% $1,802,635
GEODE CAPITAL MANAGEMENT, LLC 0.93% 523,899 +20% 0% $1,755,983
JANE STREET GROUP, LLC 0.93% 521,072 +1382% 0% $1,745,592
MARSHALL WACE, LLP 0.91% 511,858 +144% 0% $1,714,723
BlackRock, Inc. 0.84% 471,989 +37% 0% $1,581,164
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.61% 345,095 0% $1,156,068
HighTower Advisors, LLC 0.58% 328,500 +6.5% 0% $1,100,475
683 Capital Management, LLC 0.42% 238,177 0.07% $797,893
STATE STREET CORP 0.41% 230,611 +16% 0% $772,547
GOLDMAN SACHS GROUP INC 0.41% 229,695 0% $769,478
Union Square Park Capital Management, LLC 0.4% 224,746 0% 0.59% $752,899
Cerity Partners LLC 0.34% 189,789 0% $635,793
Alphabet Inc. 0.34% 189,122 0% 0.02% $633,559
TWO SIGMA INVESTMENTS, LP 0.32% 180,950 +1100% 0% $606,183
SIMPLEX TRADING, LLC 0.3% 167,201 +89% 0.02% $560,123
CITADEL ADVISORS LLC 0.28% 155,928 +174% 0% $522,359

Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 20,143,303 $67,479,982 +$28,429,772 $3.35 67
2025 Q3 11,792,663 $19,221,893 +$6,863,060 $1.63 45
2025 Q2 7,578,787 $12,505,248 +$3,952,656 $1.65 40
2025 Q1 5,230,260 $6,956,589 +$1,241,119 $1.33 35
2024 Q4 5,108,991 $9,553,550 +$495,078 $1.87 34
2024 Q3 5,193,769 $4,039,786 -$775,970 $0.78 32
2024 Q2 6,247,425 $4,679,876 -$811,761 $0.75 41
2024 Q1 7,272,011 $7,707,118 -$189,424 $1.06 44
2023 Q4 7,451,323 $7,825,763 -$54,129 $1.05 41
2023 Q3 7,501,451 $8,401,710 -$2,281,471 $1.12 40
2023 Q2 8,974,632 $13,507,225 +$1,945,492 $1.50 38
2023 Q1 7,677,996 $11,976,762 +$3,808,602 $1.56 41
2022 Q4 5,400,142 $3,438,849 -$3,310,463 $0.64 46
2022 Q3 9,314,202 $12,384,077 -$3,927,969 $1.33 51
2022 Q2 11,700,511 $25,971,549 -$20,267,021 $2.22 60
2022 Q1 14,236,792 $88,111,251 -$45,899,789 $6.19 83
2021 Q4 19,237,596 $242,781,654 -$219,571,461 $12.62 95
2021 Q3 19,191,414 $1,759,087,977 +$80,924,604 $91.66 130
2021 Q2 18,545,330 $982,908,976 -$6,104,699 $53.00 104
2021 Q1 18,693,040 $673,491,454 +$37,011,077 $36.03 90
2020 Q4 17,656,872 $490,520,403 +$26,833,435 $27.78 84
2020 Q3 16,543,535 $826,995,550 +$55,308,755 $50.00 85
2020 Q2 15,442,796 $714,739,484 +$184,954,170 $46.30 82
2020 Q1 11,450,501 $522,757,976 +$39,593,805 $45.61 65
2019 Q4 10,588,023 $594,414,680 +$91,850,250 $56.14 51
2019 Q3 5,847,617 $144,973,494 +$81,320,822 $24.93 41
2019 Q2 2,421,805 $102,945,360 +$102,944,765 $42.51 37